On-Body Drug Delivery Devices Expanding Into Oncology Treatments
The market for on-body drug delivery devices is growing as wearable injectors move into oncology and biologic treatments. High-volume biologics are shifting from infusion chairs to wearable administration.
The market for on-body drug delivery devices is entering a more commercially significant phase, with wearable injectors expanding beyond established chronic disease applications into complex biologic and oncology treatments.
According to DataM Intelligence, this shift enables high-volume biologics to transition from hospital infusion chairs to administration via wearable devices at home. This transition can improve patient adherence and reduce healthcare costs.
Devices capable of handling low to medium viscosities have proven effective for long-term applications. Developments in new technologies are further supporting the adoption of these wearable, in-vivo administration devices across various therapeutic areas.
The market is expected to see substantial growth as more pharmaceutical companies adopt wearable delivery solutions for advanced therapies. Specialty areas like oncology are anticipated to benefit significantly from this trend, given the need for prolonged and precise drug dosage.